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Background: Hepatocellular carcinoma (HCC) is the most frequent and aggressive primary tumor of the liver and it
has limited treatment options.
Results: In this study, we report the in vitro and in vivo effects of two novel amino-trifluoro-phtalimide analogs, Ac-915
and Ac-2010. Both compounds bind lipid droplets and endoplasmic reticulum membrane, and interact with several
proteins with chaperone functions (HSP60, HSP70, HSP90, and protein disulfide isomerase) as determined by affinity
chromatography and resonant waveguide optical biosensor technology. Both compounds inhibited protein disulfide
isomerase activity and induced cell death of different HCC cells at sub or low micromolar ranges detected by classical
biochemical end-point assay as well as with real-time label-free measurements. Besides cell proliferation inhibiton,
analogs also inhibited cell migration even at 250 nM. Relative biodistribution of the analogs was analysed in native
tissue sections of different organs after administration of drugs, and by using fluorescent confocal microscopy based
on the inherent blue fluorescence of the compounds. The analogs mainly accumulated in the liver. The effects
of Ac-915 and Ac-2010 were also demonstrated on the advanced stages of hepatocarcinogenesis in a transgenic
mouse model of N-nitrosodiethylamine (DEN)-induced HCC. Significantly less tumor development was found in the
livers of the Ac-915- or Ac-2010-treated groups compared with control mice, characterized by less liver tumor incidence,
fewer tumors and smaller tumor size.
Conclusion: These results imply that these amino-trifluoro-phthalimide analogs could serve potent clinical candidates
against HCC alone or in combination with dietary polyunsaturated fatty acids.
Keywords: Hepatocellular carcinoma, Lipid droplet, Heat-shock proteins, Protein disulfide isomerase, Reactive
oxigen speciesBackground
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer of men, while the eighth most frequent can-
cer of women worldwide, and the second leading cause
of cancer death [1,2]. The majority of HCC cases are as-
sociated with chronic hepatitis or cirrhosis induced by* Correspondence: puskas.szbk@gmail.com
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stated.persistent infection with hepatitis B or hepatitis C virus
[3]. Despite advances in different chemotherapies which
are often associated with toxic side effects, liver cancer
has limited treatment options. More effective therapeutic
agents with fewer side effects are in the focus of current
research.
Novel thalidomide analogs, Ac-915 and Ac-2010 (4-
amino-substituted 2,6-diisopropylphenyl- -5,6,7-trifluor-
oisoindole-1,3-diones) were synthesized from starting
tetrafluoro thalidomide based on our previously publishedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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blue fluorescence, like the previously synthesized ones [4],
and in the present study their intracellular and tissue distri-
bution were detected based on their fluorescent character-
istics. Here, we demonstrated that Ac-915 and Ac-2010,
novel amino-trifluoro-phtalimide analogs with novel sub-
stitutions also interfere with lipid droplets and the endo-
plasmic reticulum (ER), and induce intracellular reactive
oxygen species (ROS) at lower concentrations than the
previously described compounds. The novel compounds
described here, specifically interact with lipid droplet-
associated proteins, protein disulfide isomerase (PDI) and
heat-shock proteins (HSPs) that are involved in chaperone
functions. The upregulation of HSPs, as observed in vari-
ous cancers, including liver cancer suggests that they might
be involved in carcinogenesis [5-7]. Knockdown of PDI ac-
tivity can cause accumulation of misfolded proteins in the
ER, activation of apoptotic signaling, and induction of
caspase-dependent apoptosis in breast cancer cells [8].
Here we investigated the possible PDI inhibition of the
novel analogs by using enzymatic assays.
Lipid droplets (LDs) are one of the main intracellular
targets of amino-trifluoro-phtalimide analogs. It was
shown that LD accumulation occurs in vivo in prenecro-
tic cancer tissues, therefore LDs can serve as in vivo
markers of cancer [9]. Imbalance in lipid homeostasis
can finally lead to membrane disruption and activation
of lipoapoptosis [10]. As LDs are formed in the ER we
were able to show that specific LD-binding drugs could
interfere with LD homeostasis and ER-membrane integ-
rity and could trigger apoptosis through ER stress [4].
Tumors, including hepatocellular carcinoma are more
sensitive to ER stress and reactive oxygen species (ROS)-
inducing natural compounds, such as polyunsaturated
fatty acids (PUFAs) and celestrol among others [4,11]
than normal cells as their stress response is continuously
engaged due to their chronic stress situation, thereby
leading to activation of pro-apoptotic signals and fi-
nally tumor cell death [12].
Loss of lipid droplets in hepatic stellate cells is one of
the first events observed in the development of liver dis-
ease leading to HCC, mostly due to the dramatic drop in
cellular retinyl ester content [13]. Surprisingly, in study
Blaner and co-workers showed that Lrat KO mice, which
lacks the sole enzyme responsible for hepatic retinyl
ester synthesis, showed significantly less liver tumor de-
velopment compared with wild-type mice, as character-
ized by less liver tumor incidence and smaller tumor
size [14].
On the contrary, the liver of matrilin-2 KO (Matn2−/−)
mice contained macroscopic tumors of both larger
number and size than the wild-type liver after diethyl-
nitrosoamine (DEN) treatment. DEN is widely used
as a carcinogen in experimental animal models. Uponintraperitoneal administration into weaning mice at 2 weeks
after birth, hepatic tumors are formed 8 month later [15].
Since DEN itself does not exert carcinogenicity, it needs to
be bioactivated by cytochrome P450 enzymes in the liver,
resulting in DNA-adducts that form through an alkylation
mechanism locally, which induce the formation of putative
preneoplastic lesions [16].
Owing to the increased number and size of the DEN-
induced liver tumors in the transgenic Matn2−/− mice,
we used this in vivo model to assess the efficacy of our
novel amino-trifluoro-phtalimide analogs. The worth-
while in vivo efficacy data presented here anticipate the
completion of pre-clinical studies and initiate a clinical
study on evaluating the effects of Ac-915, or the more




Hep3B and HepG2 cells were grown in mixture of
Dulbecco’s Modified Eagle Medium (D-MEM) (high
glucose) (Gibco BRL, Carlsbad, CA, USA) and Nutrient
Mixture F-12 Ham (Sigma, St. Louis, MO, USA) contain-
ing penicillin (50 IU/ml)–streptomycin (50 mg/ml) and
10% fetal bovine serum. For cytotoxicity assays, cells were
seeded at a density of 10.000 cells per well into 96-well
cell culture plates and maintained in a humidified atmos-
phere of 95% air and 5% CO2 for 12 h, then treated with
different concentrations of Ac-2010 or Ac-915. MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) assay was applied to drug
treated and control (0.2% DMSO) cells with CellTiter 96®
AQueous Assay (Promega, Madison, WI) according to the
manufacturer’s protocol.
Intracellular localization
HepG2 cells were cultured in glass bottom culture
dishes (MatTek Corporation, Ashland, MA). ER was la-
beled in live cells with ER-Tracker Green (Invitrogen,
Carlsbad, CA) following the manufacturer’s protocol.
After staining the solution was replaced by fresh Hank’s
Balanced Salt Solution with calcium and magnesium
containing 5 μM Ac-915 or Ac-2010 and 5 min later the
cells were visualized using an Olympus Fluoview FV1000
confocal laser scanning microscope equipped with 20x
(N.A 0.75) and 40x oil (N.A 1.3) objectives. We applied
a 543 nm laser for detection of the ER-Tracker Green
and 405 nm laser for detection of Ac compounds [17].
Tissue distribution
Mice were injected i.v. with Ac-915 or Ac-2010 (20 mg/kg)
and after different time points tissues were dissected,
washed in PBS, embedded in Tissue-Tek® O.C.T™ medium.
After fast-freezing, the samples were stored at −20°C.
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CM1950 cryostat at −20°C. From each tissue (liver, brain,
kidney, muscle, heart) three independent images were re-
corded as above. Images were analyzed with the Olympus
Fluoview 1.6 Ver Viewer software.
Affinity chromatography and protein identification
Ac-201 compound, a previously described trifluoro-amino-
phtalimide analog [4] was covalently attached to activated
controlled pore glass resins by using the AviLink™
technology (Avicor, Szeged, Hungary, www.avicorbio-
tech.com) [18]. After blocking and washing the columns,
whole cell lysate from 6×107 RVH cells was applied onto
the column with 1 ml resin in PBS containing protease
inhibitors. After washing the columns with 20 ml each of
0.2 M and 0.5 M NaCl in PBS, proteins were eluted with
1% SDS in PBS and applied to polyacrylamide gel-
electrophoresis. Specific protein bands were cut out and
stored at 4°C until further processing for mass spectrom-
etry analysis. Samples were processed for mass spectrom-
etry by using the UCSF in-gel digestion protocol (http://
donatello.ucsf.edu/ingel.html). LC-MS analysis was per-
formed by using the Agilent 1100 LC-MS/MS system with
Zorbax 300SB-C18, 5 μm, 5mmx0,3 mm and Zorbax
300SB-C18, 3.5 μm, 150x0,075 mm columns). MS-method:
Scan: m/z 300–1600, MS2 Scan: m/z 100–1800.
Waveguide optical biosensor assay
Protein immobilization was accomplished by applying
10 μL of 50 μg/mL human PDI (Sino Biological Inc.,
Beijing, China) or 50 μg/mL human HSP70 (Sino Bio-
logical) or 100 μg/mL human HSP90 (Sino Biological) in
20 mM sodium acetate pH 5.5 into a preactivated 384-
well biochemical plate (Perkin Elmer) and incubating
overnight at 4°C. The microplates were subsequently
washed three times with assay buffer (PBS, pH 7.4/0.005%
Tween 20/3% DMSO) and, after 25 minutes thermal
equilibration, a baseline reading was taken in the Enspire
Multimode Plate Reader (Perkin Elmer). Finally, 15 μL
assay buffer was added including different concentrations
of Ac-915 or Ac-2010. The Enspire response is measured
as a shift in reflected wavelength and is expressed in pic-
ometers (pm). The affinity (KD) was calculated using a
curve fitting method.
Protein disulfide isomerase assay
The assay is based on the measurement of the catalytic
reduction of insulin as described by Lundstrom and
Holmgren [19]. In this assay, PDI facilitates the reduc-
tion of insulin in the presence of DTT. The reduced in-
sulin chains aggregate, and the turbidity is monitored
spectrophotometrically at 650 nm. The assay was per-
formed in a 96-well plate format and a volume of 30 μl
in the presence of 1 mM DTT, 1 μg PDI (Sino Biological),0.14 mM bovine pancreas insulin (Sigma), and 0.2 mM
EDTA in 100 mM potassium phosphate, pH 7.0. The
progress of the reaction was monitored on a 96-well
plate reader (Model 680 Microplate Reader, Bio-Rad
Laboratories) at 650 nm for 95 minutes at 25°C. Ac-915,
Ac-2010 or DMSO control was added prior to the addition
of enzyme at the concentrations indicated. The nonenzy-
matic reduction of insulin by DTT was recorded in a con-
trol well without PDI. IC50 values of the compounds were
calculated using nonlinear regression analysis.
Real-time cellular analysis with the xCELLigence System
Cytotoxicity and cell migration was monitored with the
real-time cell electronic sensing, xCELLigence System
(RT-CES, Acea-Roche) [20,21]. Cytotoxicity effects of Ac-
2010 and Ac-915 compounds were tested on two different
hepatocellular carcinoma cell lines (HepG2 and Hep3B).
The RT-CES 96-well E-plate was coated with gelatin and
then washed twice with PBS. Growth media (respective to
cell types) were then gently dispensed into each well of the
96-well E-plate for background readings by the RT-CES
system prior to addition of cell suspension at a density of
6000 cells/well. Devices containing the cell suspension
were kept at 37° in a CO2 incubator for 8 h prior to treat-
ment with different concentrations of Ac-2010 and Ac-
915. Cell growth was monitored for 48 h by measurements
of electrical impedance every 5 min.
For migration assay, 160 μl of media containing 10%
FBS was added to the lower chambers of CIM-plate 16.
Wells of the upper chamber sealed at the bottom with a
micro-pore-containing polycarbonate were filled with
Hep3B cell suspension (20,000 cells/well) in 100 μl
serum-free medium. Cell migration to lower chamber
was monitored and expressed as cell index value. Con-
tinuous recording of impedance in cells of both systems
was reflected by cell index value.
ROS determinations
ROS generation was determined by the increase in
DCFDA (2',7'-dichlorodihydrofluorescein diacetate, Sigma)
fluorescence after drug stimulation. HepG2 cells were
washed, resuspended in 1% bovine serum albumin in
Hanks buffered saline solution (BSA-HBSS) at 106 cells/mL
and maintained at 37°C for analysis. Cells were treated with
the indicated drugs (Ac-915, Ac-2010). DCFDA was added
60 min prior to harvest, at 2 μM final concentration and
intracellular ROS production was measured by using a
fluorescence activated cell sorter (Beckton Dickinson) with
20,000 events/test. All the other parameters and calcula-
tions were as described before [4].
Glutathione measurements
HepG2 cells (20000 cells per well in a 96-well plate)
were incubated with Ac-915 in 50 μl PBS for 2 hours in
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aliquots of prepared 2X GSH-GloTM Reagent (GSH-
GloTM Glutathione assay; Promega, Madison, WI) were
added to the wells and incubation continued at room
temperature for 30 minutes. 100 μl of reconstituted Lucif-
erin Detection Reagent (Promega) was added to each well
and cells were incubated for 15 minutes further. Negative
controls and blank reactions were also prepared. The
amount of light produced was detected by luminometer.
Animal maintenance and treatments
All mice were fed a commercial diet and water ad libi-
tum and were housed in an animal facility under a 12 h
light/dark cycle at constant temperature and humid-
ity. For all of our studies, we employed male Matn2-
deficient mice (Matn2−/−) congenic in the 129/Sv genetic
background [22].
For studies of liver tumor development, 15-day-old
mice were treated with a single dose of DEN (Sigma-
Aldrich, Budapest, Hungary) dissolved in saline at a dose
of 25 mg/kg body weight by i.p. injection. 4 months after
DEN injection mice were treated with either Ac-915 for
3 months (n = 15) or with Ac-2010 for 1 month (n = 10).
Mice were killed 8 months after DEN administration
for determination of tumor occurrence (number of
tumor nodules) and liver mass index (liver weight/body
weight × 100). Treatments were conducted by i.p. injec-
tion of Ac-915 at a dose of 10 mg/kg body weight three
times a week or Ac-2010 at a dose of 4 mg/kg body weight
three times a week.
Animal ethic
The animal experiments were performed according to
Institutional and National Animal Experimentation and
Ethics Guidelines in possession of an ethical clearance
(XVI/03047-2/2008).
Results
In vitro effect on cell proliferation and migration
Two novel amino-trifluoro-phtalimide analogs synthe-
sized by Avidin Ltd. Ac-915 (2-[2,6-bis(propane-2-yl)
phenyl]-4-{[(3R)-1,1-dioxo-2,3-dihydro-thiophene-3-yl]
amino}-5,6,7-trifluoro-2,3-dihydro-1H-isoindole-1,3-dione)
and Ac-2010 (2-[2,6-bis(propane-2-yl)phenyl]- 5,6,7-
trifluoro-1,3-dioxo-2,3-dihydro-1H-isoindole-4-yl}-3-(2-
chloroacetyl)urea) showed superior cytotoxic activity in
cancer cells and therefore were selected to the present
study. Their cytotoxic effects on human hepatocellu-
lar carcinoma cell lines (namely: HepG2, Hep3B and
Huh7) were measured by using the MTS assay. EC50
values for 48 h exposure were summarized next to their
chemical structures in Figure 1. Both Ac-915 and Ac-
2010 induced cell death of liver cancer cells at sub- or
low micromolar ranges.Cytotoxic effects of Ac-915 and Ac-2010 compounds
were also tested by the real-time cell electronic sensing,
xCELLigence System (RT-CES) on two different hepato-
cellular carcinoma cell lines (Huh7, HepG2). This tech-
nology is based on proprietary microelectronic cell
sensor arrays that are integrated in the bottom of the mi-
crotiter plates (96-well E-plate). When cells are cultured
in a well, impedance is measured between sensor elec-
trodes and the attached cells that act as insulators, which
is converted into cell index number [20,21]. As shown in
Figure 2a both analogs exerted micromolar cytotoxic ef-
fects on both liver cancer cell lines used. These results
are in good correlation with data obtained by using the
biochemical assay.
To determine whether our novel compounds have
only effects on cell proliferation or they inhibit cell mi-
gration, the same technology was used. Cell migration
was followed in real-time by using the RTCA DP xCEL-
Ligence System (Acea-Roche). This is a novel cell migra-
tion and invasion assay system that uses the Boyden
Chamber principle but the bottom chamber has a micro-
pore-containing polycarbonate membrane, which con-
tains microelectronic sensor arrays on its bottom surface.
Migration of cells is detected when cells go through these
electrodes, which changes impedance, and will increase
cell index. As seen in Figure 2b Ac-2010 inhibited migra-
tion even at 250 nM, where no cytotoxicity could be de-
tected in case of HepG2 cells. At higher concentration
the drug completely inhibited cell migration 2 h after
administration.
Mechanism of action
To gain insight into the association of the new analogs
with their physiological targets, we identified target pro-
teins in total cell lysates of human tumor cells by affinity
chromatography. In order to determine the interacting
proteins of trifluoro-amino-phtalimides the AviLink™
technology (Avicor Ltd.) was applied that enabled us to
prepare affinity resins. After washing and elution of the
columns, the eluates were analyzed on polyacrylamide
gels. Gel pieces corresponding to specific protein tar-
gets were cut out and submitted to mass spectrometry-
based protein identification. The results are summarized
in Table 1. Among the hits we found several proteins
that were previously shown to be lipid droplet-associated
(such as fatty acid synthase, SEC22B, HSP60, HSP70,
HSP90, calnexin, β-tubulin, RAB7, RAB10, RAB11,
and protein disulfide-isomerase A6 (PDI)). Other pro-
teins (Reticulon-3, SEC22B, and Neutral alpha-glucosidase
AB) were previously shown to be localized to ER and
Golgi.
In Table 1 the possible function of the protein targets
can be also seen. The protein target functions can be clas-
sified in three major classes: 1) vesicular and membrane
Figure 1 Chemical structure of trifluoro-amino-phthalimides: Ac-915 and Ac-2010 and their EC50 values in different liver cancer
cell lines.
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Direct biomolecular interactions were determined be-
tween human recombinant and purified HSP70, HSP90,
PDI proteins and Ac-915 and Ac-2010 with resonant
waveguide optical biosensor technology in a biochemical
binding assay [23]. The technology is based on a micro-
plate with resonant waveguide optical biosensors integrated
into each well and a high throughput screening-compatible
optical reader (Enspire system, Perkin Elmer). The bio-
chemical interaction between the small molecule and the
protein was measured as a shift in reflected wavelength
and is expressed in picometers (pm). The binding of both
analogs to each of the protein was specific and saturable
with the dose response (data not shown). The affinity (KD)
values were calculated as follows for Ac-915: HSP70 KD:
14 μM, HSP90 KD: 11.5 μM and PDI KD: ≈10.5 μM; for
Ac-2010: HSP70 KD: ≈16 μM, HSP90 KD: ≈16 μM and PDI
KD: ≈6 μM.
The upregulation of HSPs as observed in various can-
cers, including liver cancer suggests that they might be
involved in carcinogenesis. In particular, the enhance-
ment of carcinogenesis via the overexpression of HSP60,
HSP70 and HSP90 has been previously implicated in
animal models [9] and in clinical samples [5-7,24]. Because
of the stressful cancerous microenvironment, tumor cells
strived to increase the expression of chaperone proteins for
cytoprotective function and to enhance tumor growth and
metastasis, therefore inhibition of their chaperone function
is a logical option for cancer treatment.
As amino-trifluoro-phtalimide thalidomide analogs
possess strong inherent blue fluorescence, intracellular
localization can be easily performed on live cells. The sub-
cellular localization of the new thalidomide analogs Ac-915
and Ac-2010 was determined by fluorescent microscopyin human liver cancer cells. Previously we determined
that amino-trifluoro-phtalimides stain lipid droplets and
some of their derivatives were co-localized to ER [4,17].
In order to assess the localization of the two novel com-
pounds, we incubated HepG2 human HCC cells in
culture medium containing Ac-915 or Ac-2010 and per-
formed fluorescent microscopy. Both compounds showed
ER-specific localization as presented for Ac-2010 in
Figure 3a-c. Ac-2010 pseudocolored red gives yellow
signals upon colocalization with ER-specific green signals.
Red dots inside the cell correspond to lipid droplets that
ER tracker does not stain.
Intracellular localization studies were in good concord-
ance with our target identification results, where most of
our hits were localized to ER or lipid droplets.
Based on the affinity target identification and co-
localization results, PDI was selected to study whether
our novel amino-trifluoro-phtalimide analogs influence
its enzymatic activity. PDI is a multifunctional 57-kDa
oxidoreductase of the thioredoxin superfamily that cata-
lyzes the formation, cleavage and rearrangement of disul-
fide bonds and, by acting as a molecular chaperone, it
facilitates protein folding [25]. PDI is expressed mainly in
the ER of eukaryotic cells, where it predominantly forms
disulfide bonds in nascent secretory proteins. It catalyzes
the rearrangement of incorrect disulfide bonds through
isomerase activity, thus supporting proper protein folding
mainly during cellular stress, but during normal cellular
conditions as well [26]. Loss of PDI activity can cause ac-
cumulation of misfolded proteins in the ER, i.e. ER stress
and subsequently induce cell death. Hashida et al. pre-
sented that PDI-knockdown activated apoptotic signaling,
resulting mitochondrial cytochrome c release, activation of
different caspases, and finally it induces caspase-dependent
apoptosis in MCF7 cells [8].
Figure 2 Real-time analysis of cytotoxicity of Ac-915 and Ac-2010 against (a) Huh7 and (b) HepG2 cells. Arrow shows the starting point
of treatment of the cells. Each cell index value was normalized to this starting point. (c) Real-time analysis of the inhibitory effects on HepG2 cell
migration. Average cell index values were calculated from four biological replicas. Standard deviation of each value is shown in each curve.
(Numbers after compound codes are concentrations in nM).
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activity of PDI with about 15 μM and 9 μM IC50 values,
respectively. These values are in good correlation with the
KD values determined by direct biochemical interaction
measurements using waveguide optical biosensors. Theactivity of PDI was based on the measurement of the
catalytic reduction of insulin as described by Lundstrom
and Holmgren [19]. In this assay both analogs inhibited
the PDI-induced reduction of insulin in the presence
of dithiothreitol. The reduced insulin chains aggregated
Table 1 Trifluoro-phtalimide-associated proteins from human cancer cells
Entry name Function Subcellular location
14-3-3 protein epsilon Signal transduction Cytoplasm, lipid droplet
Aldehyde dehydrogenase, mitochondrial Alcohol metabolism Mitochondrium, lipid droplet
Calcyclin-binding protein Proteosomal degradation of proteins Nucleus, cytoplasm
Calnexin MHCI antigen-binding Lipid droplet
Dimethylaniline monooxygenase Oxidation of drugs, pesticides, xenobiotics Microsome
Hsp 60 Chaperone Mitochondrium, lipid droplet
Hsp 70 kDa protein 5 (GRP 78) Chaperone ER, lipid droplet
Hsp 90-alpha Chaperone Cytoplasm, lipid droplet
Hsp 90-beta Chaperone Cytoplasm, lipid droplet
Leucine-rich repeat-containing protein 59 Regulate nuclear import Microsome
Long-chain-fatty-acid-CoA ligase 3 Lipid biosynthesis, fatty acid degradation Mitochondrium, peroxisome, microsome, lipid droplet
Membrane-associated progesterone receptor 1 Receptor for progesterone Microsome
Neutral alpha-glucosidase AB precursor Maturation of glycoproteins ER, Golgi
Phosphate carrier protein, mitochondrial Phosphate transport Mitochondrium
Prenylcysteine oxidase Degradation of prenylated proteins Lysosome
Protein disulfide-isomerase A6 Chaperone ER, lipid droplet
Protein FAM10A5 Suppression of tumorigenicity Cytoplasm
Ras-related protein Rab-7 Vesicular trafficking Endosome, lysosome, phagosome, lipid droplet
Ras-related protein Rab-10 Vesicular trafficking, neurotransmitter release Cell membrane, lipid droplet
Ras-related protein Rab-11B Vesicular trafficking Cell membrane, lipid droplet
Reticulon-3 Membrane trafficking ER, Golgi
Sorting nexin-2 Intracellular trafficking Endosome
T-complex protein 1 subunit zeta Chaperone Cytoplasm
Twinfilin-1 Motile, morphological processes, endocytosis Cytoplasm
Tubulin beta-2 chain Cytoskeleton, vesicular transport Cytoplasm, lipid droplet
UDP-glucuronosyltransferase 1-6 Elimination of toxic xenobiotics Microsome
Vesicle-trafficking protein SEC22b Vesicular trafficking ER, Golgi, lipid droplet
Figure 3 Intracellular localization of Ac-2010. (a) HepG2 human hepatocellular carcinoma cells were double-stained with the blue fluorescent
Ac-2010 (10 μM) pseudocolored as red, and (b) endoplasmic reticulum-specific dye (ER-TrackerTM Green). (c) Orange color derives from
colocalization of ER-TrackerTM and Ac-2010. Red spots correspond to lipid droplets as ER-tracker does not stain oil bodies, while Ac-2010
does. Scalebar is 10 μm.
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untreated samples due to the slower insulin reduction
(data not shown). Although IC50 values are higher than
the effective concentration inducing ROS, GSH depletion
and cytotoxicity, we assume that both Ac-915 and Ac-
2010 are localized in the ER and their local, subcellular
concentrations could be much higher. Therefore appro-
priate inhibition of PDI can be achieved at relative lower
concentrations applied to cells.
Toxic compounds and numerous anticancer agents
interfere with chaperone and ER functions leading to
cellular stress which is manifested by elevated reactive
oxygen species (ROS) and dramatic decrease in the anti-
oxidant, glutathione (GSH) level. To investigate whether
Ac-915 and Ac-2010 exert a pro-oxidative effect as de-
termined earlier for other amino-trifluoro-phthalimides
[4] and “redox-reactive” thalidomide analogs [27], we
measured the presence of ROS in human hepatocellular
carcinoma cells (Hep3B) Figure 4a. To reveal the correl-
ation of depletion of glutathione and ROS production of
the analogs we determined the intracellular concentra-
tions of glutathione. To determine whether Ac-915 and
Ac-2010 affect intracellular GSH levels Hep3B cells were
treated with compounds and GSH levels were recorded.
According to our expectations, by inducing oxidative
stress both compounds also depleted intracellular GSH
levels (for Ac-915 GSH levels, see Figure 4b.Figure 4 Intracellular glutathione (GSH) concentrations in Ac-915 treated
the untreated control (%). (b) ROS formation (DCFDA %) and cell death (PI %)
30 min and 60 min after treatment.There is increasing evidence that ER stress plays a cru-
cial role in the regulation of apoptosis in cancer and
normal cells [28]. ER stress leads to the production of
misfolded proteins, and as a consequence to alleviate ER
stress different chaperones and folding enzymes are up-
regulated. During this response, several pro-apoptotic
signals are activated and, depending on the extent of
the ER stress, cells undergo apoptosis [29]. Our results
further support our hypothesis that our novel amino-
trifluoro-phtalimide analogs interact with the ER and
proteins associated with it, they induce ER stress, ROS
production, decreased glutathione level and finally cell
death.
Tissue distribution
To determine the tissue distribution of trifluor-amino-
phtalimides, compounds were administered by i.v. in-
jection into mice, the animals were killed at different
time points and different organs were dissected. Native
microscope sections were prepared and analyzed under
fluorescent microscope. Because our analogs have strong
inherent blue fluorescence, relative tissue distribution
can be determined by using fluorescent microscopy with
405 nm laser with DAPI configuration. As all tissues pos-
sess inherent blue fluorescence at different intensities,
fluorescent signals of untreated control animal samples
were compared with those of treated samples. Results areHep3B cells. (a) GSH content is shown relative to values obtained with
after treatment of Hep3B cells with Ac-915 at different concentrations
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increase 1 h after administration of Ac-915 in the brain,
which implies that these analogs cannot penetrate to the
brain. There was minor fluorescence increase in the
heart, but only 4 h after administration. The target
organs of Ac-915 seemed to be the kidney and pref-
erentially, the liver. Ac-915 exhibited strong fluores-
cent signals in the liver with a peak at 4 h. Similarly,
2 and 4 h after administration strong signals could be re-
corder in the kidney.
From these results we concluded that the novel trifluor-
amino-phtalimides indeed accumulate in the liver, the
target organ of our cancer study.
In vivo effects on DEN-induced hepatocarcinoma model
Based on the increased number and size of the DEN-
induced liver tumors in the transgenic Matn2−/− mice
compared to the wild-type mice, the transgenic model
was used to assess the in vivo effects of our potent amino-
trifluor-phthalimide analogs.
For studies of liver tumor development, 15-day-old
mice were treated with a single dose of DEN as described
previously [15]. Mice in the Ac-915 treated group (n = 15)
were treated 4 months after DEN treatment for an add-
itional 3 months. Treatments were conducted by i.p. injec-
tion of Ac-915 at a dose of 10 mg/kg. Mice were killed
8 months after DEN administration and the number and
size of tumors and liver mass index were determined. Rep-
resentative photographs of the livers of DEN-induced
non-treated controls and Ac-915-treated mice are shown
in Figure 6a and b, respectively. Upon assessment of liver
tumors, we found significantly less tumor development in
the livers of the treated mice compared with that of con-
trol mice, as evaluated by less liver tumor incidence, fewer
tumors and smaller tumor size which was also represented
by the liver mass index.Figure 5 Tissue distribution of Ac-915. Tissue distribution of Ac-915 as d
samples prepared after i.v. drug administration. Dimensions of each imageTo investigate whether the other analog, Ac-2010 may
exhibit similar activity the same experiment was repli-
cated, but instead of applying the drug for 3 months Ac-
2010 was administered only for 1 month (n = 10). Liver
samples were analyzed at the same time point, 8 months
after DEN administration. Because of higher acute tox-
icity and better solubility (data not shown), Ac-2010 was
injected at a lower dose (4 mg/kg) three times a week.
Even with this protocol we obtained better result, than
with Ac-915. Significantly (p < 0.01) less liver tumor
incidence, fewer tumors and lower liver mass index
was obtained compared to the untreated control group
Figure 6c.
Drug administration was started 4 months after DEN
administration, when the early stages of carcinogenesis
ended and pre-neoplastic foci already appeared. Our
data imply that Ac-915 or Ac-2010 treated mice experi-
ence less cell proliferation and cancer progression at
later stages of liver cancer development. These findings
may open a novel chemotherapeutic intervention for pa-
tients with the cancerous stage and these analogs may
be useful in preventing HCC development.
Discussion
HCC is the most frequent and aggressive primary tumor
of the liver and it has limited treatment options. The
present study demonstrated a potent cell death-inducing
effect of two novel amino-trifluoro-phtalimide analogs,
Ac-915 and Ac-2010. Amino-trifluoro-phthalimides, which
bind lipid droplets, induce intracellular ROS formation and
ER-stress [4]. Both Ac-915 and Ac-2010 compounds in-
duced cell death of liver cancer cells at sub or low micro-
molar ranges detected by classical biochemical end-point
assay as well as with real-time measurements. Besides cell
proliferation inhibition, analogs exert cell migration inhib-
ition even at 250 nM. Cytotoxic effects of the novel analogsetermined by using fluorescent confocal microscopy on native tissue
tile is 125×125 μm.
Figure 6 In vivo effects of Ac-915 and Ac-2010 on DEN-induced carcinogenesis. (a) Representative liver samples from DEN-induced and
un-treated, Ac-915-treated (b), and Ac-2010-treated animals (c). Liver mass index and number of tumors in samples were also determined.
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of oxidative stress and depletion of intracellular GSH. The
novel amino-trifluoro-phthalimides interacted with several
proteins that localized into lipid droplets and ER. Among
their candidate protein targets are the different heat-shock
proteins (HSP60, HSP70, and HSP90) and protein disulfide
isomerase (PDI). Direct biomolecular interactions between
human HSP70, HSP90, PDI proteins and Ac-915 and Ac-
2010 were confirmed with resonant waveguide optical bio-
sensors. The activity of PDI was inhibited by both Ac-915
and Ac-2010 at micromolar concentrations.
Relative biodistribution of the analogs was analyzed in
using native tissue sections of different organs after ad-
ministration of drugs, and fluorescent confocal micros-
copy based on the inherent blue fluorescence of the
compounds. The target organs of the analogs were the
liver and the kidney. No, or minimal penetration could
be detected into the brain, the muscle or the heart.
We used the Matn2−/− mice and DEN treatment for
induction of tumors in the liver. Mice were treated ei-
ther with Ac-915 (10 mg/kg) for 3 months, or Ac-2010(4 mg/kg) for 1 months, following 4 months of DEN treat-
ment. Liver tumor assessment was conducted 8 months
after DEN administration. Significantly less tumor de-
velopment was found in the livers of the Ac-915- or
Ac-2010-treated groups compared with those of control
mice, and were characterized by less liver tumor inci-
dence, fewer tumors and smaller tumor size. These re-
sults indicate that treatment with either Ac-915 or with
Ac-2010 affected tumor progression at later stages, which
implies that these amino-trifluoro-phthalimide analogs
alone or in combination with agents or natural com-
pounds that influence ER-stress could serve potent clin-
ical candidates against HCC.
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